Radiolabeled small-molecule ligands for prostate-specific membrane antigen: In vivo imaging in experimental models of prostate cancer

Clinical Cancer Research

Volumn 11, Issue 11, 2005, Pages 4022-4028

  Foss, Catherine A ^a   Mease, Ronnie C ^a   Fan, Hong ^a   Wang, Yuchuan ^a   Ravert, Hayden T ^a   Dannals, Robert F ^a   Olszewski, Ratal T ^b   Heston, Warren D ^c   Kozikowski, Alan P ^d   Pomper, Martin G ^a,e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODOTYROSINE; LIGAND; N [N (1,3 DICARBOXYPROPYL)CARBAMOYL] S 3 IODOTYROSINE I 125; N [N (1,3 DICARBOXYPROPYL)CARBAMOYL] S METHYLCYSTEINE C 11; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; S METHYLCYSTEINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ARTICLE; CANCER SCINTISCANNING; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MALE; METASTASIS; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; XENOGRAFT;

ANIMALS; ANTIGENS, SURFACE; BINDING, COMPETITIVE; CARBON RADIOISOTOPES; CELL LINE, TUMOR; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IODINE RADIOISOTOPES; LIGANDS; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 20344374435     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2690     Document Type: Article

References (41)

1. Leach F. Targeting prostate-specific membrane antigen in cancer therapy: can molecular medicine be brought to the surface? Cancer Biol Ther 2004;3: 559-60.
2. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004;91:528-39.
3. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-81.
4. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-8.
5. Chang SS. Monoclonal antibodies and prostate-specific membrane antigen. Curr Opin Investig Drugs 2004;5:611-5.
6. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22:2522-31.
7. Troyer JK, Beckett ML, Wright GL Jr. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997;30: 232-42.
8. Ponsky LE, Cherullo EE, Starkey R, Nelson D, Neumann D, Zippe CD. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease. Prostate Cancer Prostatic Dis 2002;5:132-5.
9. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999;1:241-63.
10. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003;44:1962-9.
11. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973; 51:1409-16.
12. Bacich DJ, Ramadan E, O'Keefe DS, et al. Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate. J Neurochem 2002; 83:20-9.
13. Kozikowski AP, Nan F, Conti P, et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem 2001;44:298-301.
14. 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Mol Imaging 2002;1:96-101.
15. Kozikowski AP, Zhang J, Nan F, et al. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem 2004;47:1729-38.
16. Fraker RJ, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978;80:849-57.
17. Fuhrman S, Palkovits M, Cassidy M, Neale JH. The regional distribution of N-acetylaspartylglutamate (NAAG) and peptidase activity against NAAG in the rat nervous system. J Neurochem 1994;62:275-81
18. Jackson PF, Cole DC, Slusher BS, et al. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated α-linked acidic dipeptidase. J Med Chem 1996;39:619-22.
19. Seidel J, Vaquero JJ, Green MV. Resolution uniformity and sensitivity of the NIH ATLAS small animal PET scanner: comparison to simulated LSO scanners without depth-of-interaction capability. IEEE Nucl Sci Symp Conf Rec 2001:1555-8.
20. Lee JS, Hagemann RL, Wang Y, Tsui BMW, Pomper MG. Performance evaluation of the NIH ATLAS small animal PET system. Society of Molecular Imaging; San Francisco, CA; 2003.
21. 18F-FDG, the ATLAS small animal PET scanner, and arterial blood sampling. J Nucl Med 2004;45:665-72.
22. Yao R, Seidel J, Johnson CA, Daube-Witherspoon ME, Green MV, Carson RE. Performance characteristics of the 3-D OSEM algorithm in the reconstruction of small animal PET images. Ordered-subsets expectation-maximixation. IEEE Trans Med Imaging 2000; 19:798-804.
23. Zalutsky MR, Narula AS. A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. Int J Rad Appl Instrum [A] 1987;38:1051-5.
24. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A 1996;93:749-53.
25. O'Keefe DS, Heston WD. Clearing up the confusion over the glutamate carboxypeptidase II gene. Am J Med Genet 2004;130A:327: author reply 329-30.
26. Rong SB, Zhang J, Neale JH, Wroblewski JT, Wang S, Kozikowski AP. Molecular modeling of the interactions of glutamate carboxypeptidase II with its potent NAAG-based inhibitors. J Med Chem 2002;45: 4140-52.
27. Eckelman WC, Reba RC, Gibson RE, et al. Receptor-binding radiotracers: a class of potential radiopharmaceuticals. J Nucl Med 1979;20:350-7.
28. Slusher BS, Tsai G, Yoo G, Coyle JT. Immunocytochemical localization of the N-acetyl-aspartylglutamate (NAAG) hydrolyzing enzyme N-acetylated α-linked acidic dipeptidase (NAALADase). J Comp Neurol 1992;315:217-29.
29. Tasch J, Gong M, Sadelain M, Heston WD. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol 2001;21:249-61.
30. Tiffany CW, Lapidus RG, Merion A, Calvin DC, Slusher BS. Characterization of the enzymatic activity of PSM: comparison with brain NAALADase. Prostate 1999;39:28-35.
31. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807-11.
32. Barren RJ III, Holmes EH, Boynton AL, Misrock SL, Murphy GP. Monoclonal antibody 7E11.C5 staining of viable LNCaP cells. Prostate 1997;30:65-8.
33. Li Y, Tian Z, Rizvi SM, Bander NH, Allen BJ. In vitro and preclinical targeted α therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis 2002;5:36-46.
34. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate 2004;58:145-55.
35. Kotzerke J, Gschwend JE, Neumaier B. PET for prostate cancer imaging: still a quandary or the ultimate solution? J Nucl Med 2002;43:200-2.
36. Jain RK. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Control Release 2001;74:7-25.
37. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004;22: 969-76.
38. Lange PH. ProstaScint scan for staging prostate cancer. Urology 2001;57:402-6.
39. Jain M, Batra SK. Genetically engineered antibody fragments and PET imaging: a new era of radioimmunodiagnosis. J Nucl Med 2003;44:1970-2.
40. Chang SS, Gaudin PB, Reuter VE, O'Keefe DS, Bacich DJ, Heston WD. Prostate-specific membrane antigen: much more than a prostate cancer marker. Mol Urol 1999;3:313-20.
41. 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004;45:366-73.